Assays & Screening

— Biortus experienced drug discovery team provides a variety of screening options.

Biortus presents itself as a comprehensive early-stage preclinical drug discovery CRO that can significantly shorten the time it takes to bring a new drug candidate to clinical trials by managing your entire project from initial "hit identification" to "lead optimization".

Biortus experienced drug discovery team provides a variety of screening options, including target engagement and phenotypic screening. Identifying hit molecules is a primary objective of your project. Biortus has an extensive range of testing equipment and skilled personnel dedicated to assay development, covering biochemical, biophysical, and cell-based assays for hit identification and validation. You will gain early insights into structure-activity relationships (SAR) and mechanisms of action (MOA), empowering you to make informed go/no-go decisions. As your one-stop provider for high-throughput screening, we are committed to advancing your novel therapeutic discovery.

Hit Discovery

Lead generation

  • Multiple libraries to chose

    Lead-like

    Covalent

    Fragment

    Molecular glue

    DEL through collaboration

  • Comprehensive HTS triage strategy for your target

    Design,development,validation of primary screening assay

    Design and develop secondary/counter/orthogonal assays

    Screening condition and triage path recommendations

  • Multiple formats

    Biophysical assays

    Biochemical assays

    Cell-based assays

    Label free

    High Content Analysis

  • Mature experiences on target analysis

    Target degradation assays

    Kinase panel assays

    DUBs panel assays

    GPCR panel assays

  • Well equipped for QC of reagents, binding affinity test, and functional test in low, medium, and high through-put formats.

Libraries

Biophysical Assays

Assay types

Biochemical Assays

Biochemical Assays

Cell-based Assays

Target specific platforms

  • 1

    TPD platform

    PROTAC

    Molecular Glue

  • 2

    Kinase platform

    A total of~300 kinases available

    MSA (Caliper) assay ready for~300 targets

    ADP-GLO assay ready for>100 targets

    SPR assay ready for>60 targets

  • 3

    Dubs platform

    39 biologically active DUBs for Custom Assay Development and HTS

    18 ready to use assay kits for HTS and validation

  • 4

    GPCR platform

    GPCR surface expression validation

    GPCR signal transduction research

    GPCR biased signaling

    GPCR compound/ligand binding

    GPCR pharmacological study